Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4000247 | Urologic Oncology: Seminars and Original Investigations | 2012 | 5 Pages |
Abstract
Castrate resistant prostate cancer is a disease state which, counterintuitively, can be successfully treated with additional therapy directed at inhibition of androgen synthesis and/or interfering with the activity of the androgen receptor. Novel androgen biosynthesis inhibitors and antiandrogens are now being tested in large phase 3 clinical trials to clarify their role in the treatment of men who have failed traditional medical castration, with or without currently available nonsteroidal antiandrogens. A renewed interest in studying parenteral delivery of estrogens may provide evidence to revisit the initial medical therapy for advancing prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Paul Schellhammer,